Skip to main
DWTX

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics Inc., a development-stage biotechnology company, is focused on advancing antiviral therapies that address virus-triggered immune responses, particularly for conditions like fibromyalgia and long COVID. The company's strong potential for future revenues has prompted an increase in financial projections, with analysts raising their 12-month price target from $10 to $12 per share. Additionally, the recent licensing agreement with Serpin Pharma for the global rights to SP16 in cancer-related pain indications further enhances Dogwood's growth prospects and market positioning.

Bears say

Dogwood Therapeutics Inc, previously known as Virios Therapeutics Inc, operates as a development-stage biotechnology firm concentrating on antiviral therapies for conditions like fibromyalgia and long COVID. The company has yet to demonstrate significant revenue generation or market penetration, raising concerns regarding its long-term financial viability and the commercial success of its lead product candidates IMC-1 and IMC-2. Additionally, the ongoing challenges related to clinical development timelines and regulatory approvals may hinder investor confidence and contribute to a more negative market perception of its stock.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.